Characterization of the novel HLA-C*06:312 allele by two next-generation sequencing methods.

The novel HLA-C*06:312 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-B*42:01:05 allele by two next-generation sequencing methods.

The novel HLA-B*42:01:05 allele was characterized using two next generation sequencing technologies.

HLA-DRB1*03:190, a novel HLA-DRB1 allele suspected with microlymphocytoxicity and confirmed by sequencing.

The novel HLA-DRB1*03:190 allele was characterized using two next generation sequencing technologies.

HLA-C*01:224N, a novel null HLA-C allele characterized by two next-generation sequencing methods.

We describe here the novel HLA-C*01:224N allele which has a premature stop codon in exon 3.

Characterization of the novel HLA-A*01:405 allele by two next generation sequencing methods.

The novel HLA-A*01:405 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-A*01:406 allele by two next generation sequencing methods.

The novel HLA-A*01:406 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-C*06:346 allele by two next-generation sequencing methods.

The novel HLA-C*06:346 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-DRB1*11:296 allele by two next-generation sequencing methods.

The novel HLA-DRB1*11:296 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-B*55:122 allele by two next-generation sequencing methods.

The novel HLA-B*55:122 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-A*03:425 allele by two next-generation sequencing methods.

The novel HLA-A*03:425 allele was characterized using two next-generation sequencing technologies.

Characterization of the novel HLA-C*02:207 allele by two next-generation sequencing methods.

The novel HLA-C*02:207 allele was characterized using two next generation sequencing technologies.

HLA-B*48:53, a novel HLA-B allele with two exonic mutations.

The novel HLA-B*48:53 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-C*07:977 allele by two next-generation sequencing methods.

The novel HLA-C*07:977 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-C*05:01:68 allele by two next-generation sequencing methods.

The novel HLA-C*05:01:68 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-B*15:10:08 allele by two next-generation sequencing methods.

The novel HLA-B*15:10:08 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-B*40:02:35 allele by two next-generation sequencing methods.

The novel HLA-B*40:02:35 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-C*07:01:105 allele by two next-generation sequencing methods.

The novel HLA-C*07:01:105 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-A*23:118 allele by two next-generation sequencing methods.

The novel HLA-A*23:118 allele was characterized using two next generation sequencing technologies.

Characterization of the novel HLA-DRB1*04:334 allele by two next-generation sequencing methods.

The novel HLA-DRB1*04:334 allele was characterized using two next-generation sequencing technologies.

Relevance of KIR gene polymorphisms in bone marrow transplantation outcome.

Natural Killer (NK) cells may be involved both in allogeneic bone marrow transplantation (BMT) rejection and graft-versus-host disease (GVHD). The physiologic functions of NK cells appear to be regulated by diverse non-inhibitory and inhibitory receptors including the killer cell immunoglobulin-like receptors (KIR). Although human leukocyte antigen (HLA) epitope mismatches are well-known causes of NK alloreactivity, the role of KIR genes in transplantation remains to be further investigated. In this study, we have evaluated whether KIR genotype differences between donors and recipients of HLA identical (related and unrelated) compared with HLA non-identical unrelated BMT, had an impact on transplantation outcome. Our results show that 5 of 15 KIR genes were always identical in donors and recipients and most variations were observed in the number and specificity of noninhibitory KIR genes. Based on the presence or absence of particular KIR genes, 70 different genotypes were obtained from all individuals. According to the donor or recipient KIR genotype, different combination patterns were described. Interestingly, when the recipient KIR genotype was "included" in the donor KIR genotype, 100% (11/11 pairs) of unrelated BMT developed GVHD compared with 60% (18/30) in all other combinations (p = 0.012). In contrast, no GVHD was observed in related BMT when the recipient KIR genotype was "included" in the donor KIR genotype (p = 0.0001). In conclusion, our results reveal a great diversity for KIR genotypes in donors and recipients of BMT and that the risk of GVHD was maximum in unrelated BMT when the recipient KIR genotype was "included" in the donor KIR genotype.